Inclusion Criteria

          1. Male or female ≥18 years old.

          2. Patients with histologically confirmed unresectable Stage III or Stage IV metastatic
             melanoma who have not been previously treated with a CD24Fc, anti-CTLA4 and
             anti-PD1/PDL1 inhibitors with documented progression.

          3. Measurable disease per RECIST v1.1 criteria using imaging scans, or peripheral lesions
             that can be adequately documented with a picture and a ruler even if they do not meet
             RECIST criteria.

          4. Patients must have lesion accessible for sequential biopsy (core needle biopsy or
             excision preferred, fine needle aspiration not eligible).

          5. ECOG performance status 0 or 1.

          6. Women of child-bearing potential must have a negative serum pregnancy test within 24
             hour of initiation of dosing and must agree to use an effective form of contraception
             during the study from the time of the negative pregnancy test up to 6 months after the
             last dose of study drug. Effective forms of contraception include abstinence, hormonal
             contraceptive in conjunction with a barrier method, or a double barrier method. Women
             of non-childbearing potential may be included if they are either surgically sterile or
             have been postmenopausal for ≥1 year. Fertile men must also agree to use an effective
             method of birth control while on study drug and up to 6 months after the last dose of
             study drug.

          7. Patients must have fully recovered from the effects of any major surgery or
             significant traumatic injury within 14 days of C1D1.

          8. Adequate hematologic, hepatic, and renal function, as defined below:

               -  Absolute neutrophil count ≥1 X 109/L,

               -  Hgb > 8 g/dL

               -  Platelet count ≥ 75 X 109/L,

               -  AST/ALT/bilirubin ≤3X ULN (patients with Gilbert syndrome can have higher
                  bilirubin levels).

               -  Creatinine ≤ 3 X ULN or calculated CrCl > 30 mL/min using Cockcroft- Gault
                  formula.

          9. Willing and able to provide written informed consent prior to any study related
             procedures and to comply with all study requirements.

        Exclusion Criteria

          1. Active secondary malignancy, unless the malignancy is not expected to interfere with
             the evaluation of safety and is approved by the Medical Monitor.

          2. Investigational drug use within 28 days of C1D1.

          3. Chemotherapy, targeted therapy, growth factors or radiation therapy within 14 days of
             C1D1.

          4. Systemic steroid therapy or any other form of immunosuppressive therapy within 7 days
             prior to C1D1.

          5. Patients with known active CNS lesions are excluded (i.e., those with radiographically
             unstable, symptomatic lesions). However, patients treated with stereotactic therapy or
             surgery are eligible if they remain without clinical evidence of disease progression
             in the brain.

          6. Has received a live vaccine within 28 days prior to C1D1.

          7. A known active and clinically significant bacterial, fungal, or viral infection.

          8. Active hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV) or
             acquired immunodeficiency syndrome (AIDS) related illness, including patients who have
             an active infection requiring systemic therapy.